Tadocizumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Integrin αIIbβ3 |
| Identifiers | |
| CAS Number | 339086-80-5  |
| ATC code | none |
| UNII | R34T642CGV  |
| Chemical data | |
| Formula | C2107H3252N562O673S12 |
| Molecular mass | 47.6 kDa |
| (what is this?) (verify) |
|
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]
The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
References
- ↑ 1.0 1.1 Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ↑ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Monoclonal antibody stubs
- Blood and blood forming organ drug stubs
